Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Core Insights - Coherus BioSciences announced final data from a Phase 2 trial of casdozokitug in combination with atezolizumab and bevacizumab for treating unresectable hepatocellular carcinoma (HCC), showing a complete response rate of 17.2% and an overall response rate of 38% [1][2][4] Group 1: Clinical Trial Results - The Phase 2 trial demonstrated an increase in overall response rate from an initially reported 27% to 38%, with complete responses rising from 10.3% to 17.2% [2][5] - The trial involved 30 treatment-naïve patients, with a primary endpoint focused on safety and tolerability, and secondary endpoints including progression-free survival (PFS) and overall response rate (ORR) [5][6] - The triplet combination of casdozokitug, atezolizumab, and bevacizumab showed promising antitumor activity and an acceptable safety profile, consistent with known adverse event profiles of the individual drugs [6][7] Group 2: Future Developments - Coherus has initiated a new randomized Phase 2 trial evaluating casdozokitug in combination with toripalimab and bevacizumab, aimed at further assessing safety and efficacy [3][8] - The new trial is expected to enroll up to 72 patients and will compare two biologically active doses of casdozokitug [8] Group 3: Mechanism and Significance - Casdozokitug is a first-in-class antibody targeting IL-27, which plays a role in suppressing anti-tumor immune responses, making it a novel target for cancer treatment [3][11] - The data from the trial support the ongoing development of IL-27 as a promising target for advanced solid tumors, addressing significant unmet needs in the treatment landscape for liver cancer [4][10]